TNFSF10 and neoplasm: Cumulative evidence from studies demonstrates that multiple tumor cells are tolerant to TRAIL-induced apoptosis, and that repeated use of TRAIL may lead to the emergence of resistance to TRAIL in some sensitive cancer cells (2–5), limiting the application of TRAIL in the treatment of many tumors.